WEHI-345 analog blocks the activity of Src kinases, which are involved in various cellular processes such as growth, differentiation, and survival, and have been implicated in the progression of several cancers and other diseases. It targets RIPK2.
Molecular Weight
415.49
Molecular Formula
C23H25N7O
Targets
RIPK2
Form
Lyophilized powder
Purity
≥98%
Identity
Confirmed by NMR/HPLC/MS.
Applications
WEHI-345 analog is employed in research to explore pathways involving Src kinase and their potential therapeutic implications in inflammation and cancer.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
